The novel FGF21 receptor/glucagon receptor/GLP-1 receptor triple agonist, DR10624, in doses of 12.5 mg, 25 mg and 50 mg reduces TG by 74.5%, 66.2% and 68.9% respectively, according to results of a Phase 2, 12-week study in 79 patients with severe hypertriglyceridaemia (500-2000 mg/dL). This compared with an 8% TG reduction in patients who received placebo (p<0.0001 for all doses vs placebo).
Educational partners and supporters
Financial support was provided as a GMG Knowledge Gap Grant from Pfizer Inc.
Financial support was provided as a GMG Knowledge Gap Grant from Pfizer Inc.
Financial support was provided as a GMG Knowledge Gap Grant from Pfizer Inc.
